Antares Pharma, Inc. (NASDAQ: ATRS) today announced the appointment of Dr. Bruce Freundlich to the position of Senior Vice President, Medical. Dr. Freundlich holds an MD from the Mount Sinai School of Medicine and an MBA from the University of Massachusetts, Amherst. He completed his rheumatology training at the University of Pennsylvania where he was subsequently a member of faculty. He is currently an adjunct professor of medicine at the University of Pennsylvania and a volunteer staff member of the Philadelphia Veterans Administration.
As the former Chief of Clinical Rheumatology at Penn, Dr. Freundlich performed the first trial in rheumatology with a recombinant protein, gamma interferon in scleroderma patients based upon prior laboratory research which he had published. He then went on into industry starting at Merck where he was a medical director of the Mid-Atlantic Region and then on to Wyeth/Pfizer where he became a multi-therapeutic Vice President of Immunology and Musculo-Skeletal Diseases. While at Wyeth, his team was the first to use remission as a primary endpoint in rheumatoid arthritis for a trial called COMET. Dr. Freundlich has authored over 100 original publications and abstracts which have been presented around the world and he has been a reviewer for the Annals of Internal Medicine, the Lancet, Arthritis and Rheumatism and multiple other journals.
“We are very pleased to welcome Dr. Freundlich to the Antares team,” said Paul K. Wotton, Ph.D., President and Chief Executive Officer. “Bruce’s broad experience both in industry and academia as a practicing and highly regarded rheumatologist will be valuable as we commercialize OTREXUP ™. Dr Freundlich is well known to his peers through his numerous publications and active participation in professional association meetings including ACR and EULAR. Everyone associated with Antares is excited about his joining the organization at a time when we are establishing our own commercial presence in the rheumatology field.”
About Antares PharmaAntares Pharma focuses on self-administered parenteral pharmaceutical products and topical gel-based medicines. The Company has received marketing approval from the U.S. Food and Drug Administration for OTREXUP™ (methotrexate) injection for the treatment of adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis and adults with severe recalcitrant psoriasis. Antares Pharma is also developing VIBEX ® QS T for testosterone replacement therapy. The Company's technology platforms include VIBEX ® disposable Medi-Jet™, disposable multi-use pen injectors and Vision™ reusable needle-free injectors marketed as Tjet ® and Zomajet ® by Teva Pharmaceutical Industries, Ltd (Teva) and Ferring Pharmaceuticals (Ferring), respectively. Antares Pharma has a multi-product deal with Teva that includes Tev-Tropin ® [somatropin (rDNA origin) for injection] human growth hormone (hGH), VIBEX ® epinephrine and several other products. Antares Pharma’s partnership with Ferring includes Zomacton ® hGH (somatropin) injection. In the U.S. Antares has received FDA approval for Gelnique 3%™ (oxybutynin) gel, a treatment for overactive bladder that is marketed by Actavis. Elestrin ® (estradiol gel) is FDA approved for the treatment of moderate-to-severe vasomotor symptoms associated with menopause, and is marketed in the U.S. by Meda Pharma. Antares Pharma has two facilities in the U.S. The Parenteral Products Group located in Minneapolis, Minnesota directs the manufacturing and marketing of the Company’s reusable needle-free injection devices and related disposables, and develops its disposable pressure-assisted Medi-Jet and pen injector systems. The Company’s corporate office and Product Development and Commercial Groups are located in Ewing, New Jersey.